DTR logo

DiagnosTear Technologies Inc. Stock Price

CNSX:DTR Community·CA$32.5m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

DTR Share Price Performance

CA$0.50
-0.20 (-28.57%)
CA$0.50
-0.20 (-28.57%)
Price CA$0.50

DTR Community Narratives

There are no narratives available yet.

Snowflake Analysis

Low risk with weak fundamentals.

3 Risks
0 Rewards

DiagnosTear Technologies Inc. Key Details

CA$0

Revenue

CA$0

Cost of Revenue

CA$0

Gross Profit

CA$0

Other Expenses

CA$0

Earnings

Last Reported Earnings
n/a
Next Reporting Earnings
n/a
0
0%
0%
0%
View Full Analysis

About DTR

Founded
2023
Employees
n/a
CEO
Shimon Gross
WebsiteView website
diagnostear.com

DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic solutions for eye diseases. It develops TeaRx Dry Eye, a CE-IVD approved test based on the TeaRx platform intended for the identification and monitoring of Dry Eye Syndrome (TeaR DES); TeaRx Red Eye for differential assessment of adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis; and TeaRx Tear Collector, a proprietary microfluidic tear collector that allows non-invasive collection of 1 microliter of tear fluid and dilution in the assay buffer for downstream analytical testing. DiagnosTear Technologies Inc. was formerly known as Oceanview Technologies Inc. and changed its name to DiagnosTear Technologies Inc. The company was incorporated in 2023 and is headquartered in Rehovot, Israel.

Recent DTR News & Updates

Recent updates

No updates